19 reports

Commonly used tests to check liver function are aspartate aminotransferase (AST), alanine transaminase (ALT), albumin, and bilirubin tests.

  • Digestive System Disorder
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hoffmann-La Roche Inc.
  • Merck & Co., Inc.

THE CONDITION OF LIVER CAN BE DIAGNOSED BY METHODS SUCH AS, BLOOD TESTS, TISSUE ANALYSIS AND IMAGING TESTS.

  • Digestive System Disorder
  • World
  • Forecast
  • Market Size
  • Hitachi, Ltd.

Hepatitis virus COBAS HBV TEST ROCHE MOLECULAR SYSTEMS P## S##-S## ## WWW. WINTERGREENRESEARCH. COM/ BLOG VERSANT HCV RNA QUALITATIVE ASSAY GEN-PROBE, INC.

  • Breast Cancer
  • Digestive System Disorder
  • United States
  • Cepheid
  • PerkinElmer, Inc.

Hepatitis virus COBAS HBV TEST ROCHE MOLECULAR SYSTEMS P## S##-S## ## WWW. WINTERGREENRESEARCH. COM/ BLOG VERSANT HCV RNA QUALITATIVE ASSAY GEN-PROBE, INC.

  • Breast Cancer
  • Digestive System Disorder
  • United States
  • Cepheid
  • PerkinElmer, Inc.
  • Market trends

In Europe, Harvoni is used for the treatment of HCV genotype ## infection; HCV genotype ## infection associated with cirrhosis and prior treatment failure; and those with HIV- ##/ HCV co-infection.

  • Digestive System Disorder
  • Market Size
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Market trends

For instance, the US celebrates May ## as Hepatitis Testing Day each year and deemed May 2014 Hepatitis Awareness Month to raise awareness of hepatitis infections and encourage the testing of high-risk populations.

  • Breast Cancer
  • Digestive System Disorder
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.

Abbott launched RealTime HCV Genotype II test, a HCV genotyping test for patients in the U. S.

  • Breast Cancer
  • Digestive System Disorder
  • North America
  • United States
  • Market Size

Harvoni was approved for pediatric patients with genotype ##, ##, ## or ## HCV infection.

  • Breast Cancer
  • Digestive System Disorder
  • Lymphoma
  • United States
  • Gilead Sciences, Inc.
  • OCT 31, 2017: HEPQUANT MAKES CHANGE TO REGULATORY TEAM

" In cases of Alcoholic Hepatitis, tests like HepQuant SHUNT may be important because liver disease severity impacts short-term (weeks or months) survival.

  • Clinical Trial
  • Digestive System Disorder
  • Medical Device
  • United States
  • Product Initiative

Primary tumor site was testis in ## patients and mediastinum in ##.

  • Breast Cancer
  • Cancer
  • Digestive System Disorder
  • United States
  • Merck & Co., Inc.

The primary outcome measures of this study are to assess the adverse events, serious adverse events, laboratory results (hematology, serum blood chemistry, hepatitis tests, standard urinalysis dipstick assessment, coagulation studies)or assessment of the incidence of pneumonitis.

  • Breast Cancer
  • Digestive System Disorder
  • Targeted Therapy
  • United States
  • Product Initiative

The primary outcome measures of this study are to assess the adverse events, serious adverse events, laboratory results (hematology, serum blood chemistry, hepatitis tests, standard urinalysis dipstick assessment, coagulation studies)or assessment of the incidence of pneumonitis.

  • Breast Cancer
  • Cancer
  • Digestive System Disorder
  • United States
  • Merck & Co., Inc.

PRIMARY TUMOR SITE WAS TESTIS IN ## PATIENTS AND MEDIASTINUM IN ##.

  • Breast Cancer
  • Digestive System Disorder
  • Monoclonal Antibody
  • Therapy
  • Merck & Co., Inc.

Primary tumor site was testis in ## patients and mediastinum in ##.

  • Breast Cancer
  • Cancer
  • Digestive System Disorder
  • Therapy
  • Merck & Co., Inc.

Antiviral responses in HCV- and HBV-infected patients have been observed as measured by declines in HCV RNA and quantitative HBV surface antigen.

  • Breast Cancer
  • Cancer
  • Digestive System Disorder
  • Therapy
  • Merck & Co., Inc.

The test group also included ## individuals with stable liver impairment, including individuals infected with HCV.

  • Breast Cancer
  • Digestive System Disorder
  • Liver Transplant
  • Transplantation
  • Novartis AG

The primary outcome measures of this study are to assess the adverse events, serious adverse events, laboratory results (hematology, serum blood chemistry, hepatitis tests, standard urinalysis dipstick assessment, coagulation studies) or assessment of the incidence of pneumonitis.

  • Breast Cancer
  • Cancer
  • Digestive System Disorder
  • United States
  • Merck & Co., Inc.

The primary outcome measures of this study are to assess the adverse events, serious adverse events, laboratory results (hematology, serum blood chemistry, hepatitis tests, standard urinalysis dipstick assessment, and coagulation studies) or assessment of the incidence of pneumonit

  • Breast Cancer
  • Cancer
  • Digestive System Disorder
  • United States
  • Exelixis, Inc.

The primary outcome measures are safety, AUC, change in HCV RNA levels, measured using Roche COBAS TaqMan HCV Test v##. ## for high pure system and proportion of patients with unquantifiable/ undetectable HCV RNA during the study.

  • Breast Cancer
  • Cancer
  • Digestive System Disorder
  • Monoclonal Antibody
  • United States